Get the Stockscreener App
0.5769
9.07%
0.0479
60 Degrees Pharmaceuticals Inc stock is traded at $0.5769, with a volume of 768.30K.
It is up +9.07% in the last 24 hours and down -58.79% over the past month.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
See More
Previous Close:
$0.529
Open:
$0.51
24h Volume:
768.30K
Relative Volume:
0.36
Market Cap:
$2.72M
Revenue:
$502.40K
Net Income/Loss:
$-7.91M
P/E Ratio:
-0.0579
EPS:
-9.972
Net Cash Flow:
$-4.32M
1W Performance:
-20.56%
1M Performance:
-58.79%
6M Performance:
-48.79%
1Y Performance:
-82.73%
1-Day Range:
$0.4701
$0.5771
1-Week Range:
$0.451
$0.7102
52-Week Range:
$0.451
$7.1988
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Name
60 Degrees Pharmaceuticals Inc
Sector
Industry
Phone
202-327-5422
Address
1025 CONNECTICUT AVENUE NW, WASHINGTON
Compare SXTP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
0.5769 | 2.72M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.27 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.65 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.63 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
Pharmaceutical Funding Alert: 60 Degrees Secures Fresh Capital Through Strategic Share Offering - StockTitan
Form 424B5 60 DEGREES PHARMACEUTICA - StreetInsider.com
How does 60 Degrees Pharmaceuticals Inc (SXTP) change from a tortoise to a hare? - SETE News
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering - citybiz
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Pharma Stock Alert: SXTP Secures Fresh Capital Through Strategic Share Offering at $0.715 - StockTitan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
SXTP stock touches 52-week low at $0.7 amid market challenges - MSN
60 Degrees Pharma Announces Closing of $1.043 Million - GlobeNewswire
60 Degrees Pharma Secures Fresh Capital: Inside the $1M Financing Deal That's Turning Heads - StockTitan
60 Degrees Pharmaceuticals announces stock and warrant sale - MSN
US Stocks Mixed; General Dynamics Earnings Top Views - Benzinga
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Pharma Company's $1M Cash Injection Comes with Hidden UpsideComplete Analysis - StockTitan
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial - Yahoo! Voices
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Gets Investigational Review Board Approval for Babesiosis Phase 2 Study - Marketscreener.com
60 Degrees Pharmaceuticals, Inc. Announces the Approval of an Investigational Review Board Commissioned Phase II Clinical Study - Marketscreener.com
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewswire
Titan Pharma (NASDAQ:TTNP) Stock Quotes, Forecast and News Summary - Benzinga
Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register
60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) Jumps 0.32 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Corn and Brent Crude calendar spread - The Globe and Mail
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates - MSN
No Bull | The Five Spot - The Globe and Mail
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.10 Consensus Target Price from Brokerages - Defense World
60 Degrees Pharmaceuticals Enrolls First Patient in Expanded Access Clinical Study for Babesiosis Treatment - Defense World
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study - Yahoo Finance
Barclays PLC Has $109,000 Stock Holdings in DLH Holdings Corp. (NASDAQ:DLHC) - Defense World
SXTP60 Degrees Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
60 Degrees Pharmaceuticals Enrolls First Patient in - GlobeNewswire
60 Degrees Pharma Launches Breakthrough Study for Stubborn Tick Disease Treatment After 80% Success - StockTitan
🚀 Wall Street Radar: Stocks to Watch Next Week - substack.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Wayfair Inc (W-N) QuotePress Release - The Globe and Mail
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Wainwright maintains neutral on SXTP stock after patent deal By Investing.com - Investing.com Australia
Wainwright maintains neutral on SXTP stock after patent deal - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sixty Degrees Pharmaceuticals and Tufts Medical Center - GlobeNewswire
60 Degrees Pharma Secures Exclusive Rights for Breakthrough Babesiosis Treatment with Tufts Medical Center - StockTitan
Insider Buying: Cheryl Xu Acquires 13,000 Shares of 60 Degrees P - GuruFocus.com
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock - Investing.com India
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock By Investing.com - Investing.com Australia
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns “Neutral” Rating from HC Wainwright - Defense World
60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data
Revenue
Net Income
Cash Flow
EPS
60 Degrees Pharmaceuticals Inc Stock (SXTP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
| XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):